CHANGES IN TUMOR NECROSIS FACTOR ALFA DURING TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS BY TRANSIMMUNIZATION METHOD

Abstract

Background: Despite the availability of a large number of treatments for multiple sclerosis with various targets, these treatments are not always effective. According to the literature, experimental studies have shown a significant decrease in tumor necrosis factor alfa (TNF-α) with the use of extracorporeal photochemotherapy. Aim: To assess changes in TNF-α in patients with multiple sclerosis during treatment with transimmunization. Materials and methods: The study recruited 13 adult patients with multiple sclerosis. Serum TNF-α was measured by immunochemiluminescence analysis (IMMULITE 1000, Siemens). The patients were treated by transimmunization, i.e. a modified photopheresis. Two hours before the procedure, Ammifurin (8-methoxypsoralene) was administered to all the patients, then their mononuclear cells were isolated under PBSC protocol with Haemonetics MCS+ cell separator. Thereafter, mononuclear cells were irradiated with ultraviolet for 90 minutes and incubated for 20 hours at 37 °С. The next day the cells were re-infused to the patients. The procedure was performed 2 times per week for 6 months, then once per 4 months. Results: Before transimmunization, mean TNF-α level in adult patients with multiple sclerosis was 9.958±0.812 pg/mL (normal, below 8.1 pg/mL). After transimmunization, its level was 6.992±0.367 pg/mL (р<0.05). Conclusion: Ultraviolet irradiation of peripheral blood monocytes with their subsequent incubation (transimmunization) led to a 30% decrease of serum TNF-α in patients with multiple sclerosis. This indicates a suppressive effect of transimmunization on TNF-α. Hence, in patients with multiple sclerosis transimmunization exerts an anti-inflammatory effect.

Keywords

• multiple sclerosis
• transimmunization
• photopheresis
• extracorporeal photochemotherapy